Alvotech(ALVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALVO Alvotech

盘后交易 02-23 18:48:37 EST

4.22

+0.08

+1.93%

盘后4.05

-0.17-4.03%

17:27 EST

最高4.28	最低3.93	成交量113.16万
今开4.12	昨收4.14	日振幅8.45%
总市值13.21亿	流通市值4.90亿	总股本3.13亿
成交额464.75万	换手率0.97%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALVO","market":"US","secType":"STK","nameCN":"Alvotech","latestPrice":4.22,"timestamp":1771880400000,"preClose":4.14,"halted":0,"volume":1131576,"hourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.22,"latestTime":"17:27 EST","volume":4697,"amount":19809.949775,"timestamp":1771885624314,"change":-0.17,"changeRate":-0.040284,"amplitude":0.040284},"delay":0,"changeRate":0.01932367149758456,"floatShares":116174008,"shares":313000000,"eps":0.23,"marketStatus":"盘后交易","change":0.08,"latestTime":"02-23 18:48:37 EST","open":4.12,"high":4.28,"low":3.93,"amount":4647525.210576,"amplitude":0.084541,"askPrice":4.49,"askSize":7,"bidPrice":4.05,"bidSize":10,"shortable":3,"etf":0,"ttmEps":0.23,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":4.14,"preHourTrading":{"tag":"盘前","latestPrice":4.12,"preClose":4.14,"latestTime":"09:29 EST","volume":2044,"amount":8569.2539492,"timestamp":1771856999999,"change":-0.02,"changeRate":-0.004831,"amplitude":0.040314},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.22,"latestTime":"17:27 EST","volume":4697,"amount":19809.949775,"timestamp":1771885624314,"change":-0.17,"changeRate":-0.040284,"amplitude":0.040284},"volumeRatio":1.452098},"requestUrl":"/m/hq/s/ALVO","defaultTab":"news","newsList":[{"id":"1114971853","title":"Alvotech公布其恩利优®（Entyvio®）拟议生物类似药关键药代动力学研究的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1114971853","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114971853?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:00","pubTimestamp":1770278415,"startTime":"0","endTime":"0","summary":"生物制药公司Alvotech近日宣布，其针对参考药物恩利优®（Entyvio®）开发的拟议生物类似药，在一项关键性药代动力学研究中取得了积极的顶线结果。该研究旨在评估候选生物类似药与参照药在健康受试者体内的药代动力学相似性。初步数据显示，研究达到了其主要终点，证明了两者在关键药代动力学参数上具有生物等效性。这一积极进展标志着Alvotech在该生物类似药的研发道路上迈出了重要一步，为其后续向监管机构提交上市申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"2608335857","title":"Alvotech盘中异动 下午盘快速跳水5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335857?lang=zh_cn&edition=full","pubTime":"2026-02-04 03:03","pubTimestamp":1770145425,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日03时03分，Alvotech股票出现波动，股价急速下跌5.08%。截至发稿，该股报5.05美元/股，成交量15.47万股，换手率0.05%，振幅7.24%。Alvotech股票所在的制药行业中，整体跌幅为1.85%。其相关个股中，Biofrontera Inc C/Wts 27/10/2026 、Caring Brands, Inc.、Evotec Se涨幅较大，苏轩堂、惠普森医药、大自然药业较为活跃，换手率分别为34.80%、20.22%、10.25%，振幅较大的相关个股有惠普森医药、苏轩堂、Caring Brands, Inc.，振幅分别为53.88%、30.51%、18.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204030346a478908b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204030346a478908b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"1173259963","title":"Alvotech与加拿大及澳新地区达成多项生物类似药候选产品的供应与商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1173259963","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173259963?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:08","pubTimestamp":1770019712,"startTime":"0","endTime":"0","summary":"生物制药公司Alvotech宣布，已与加拿大以及澳大利亚和新西兰地区的合作伙伴签署了多项供应与商业化协议。这些协议涵盖公司管线中多款生物类似药候选产品，旨在将这些高性价比的疗法引入相关市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"1184786153","title":"医保药品价格谈判第三轮选定药物公布：安诺罗易利达、必克特维、保妥适、保妥适美容针、辛齐亚、科森提斯入选","url":"https://stock-news.laohu8.com/highlight/detail?id=1184786153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184786153?lang=zh_cn&edition=full","pubTime":"2026-01-28 05:40","pubTimestamp":1769550053,"startTime":"0","endTime":"0","summary":"美国医疗保险和医疗补助服务中心近日公布了第三轮药品价格谈判的选定药物名单。此次入围的药品包括用于慢性阻塞性肺病的安诺罗易利达、治疗艾滋病的必克特维、以及广泛应用于医疗与美容领域的保妥适和保妥适美容针。此外，自身免疫疾病治疗药物辛齐亚与科森提斯也成功入选。下一步，CMS将与企业就药品价格进行直接协商，最终谈判价格将于2024年公布。此举被视为美国控制医疗成本上涨的关键措施之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","IE00B3T34201.USD","BK4583","LU1839511570.USD","LU2468319806.SGD","LU1571399168.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","GILD","SG9999015986.USD","ALVO","IE00B7SZLL34.SGD","SG9999015978.USD","LU0889565916.HKD","BK4566","SG9999015952.SGD","BK4585","IE00BKVL7J92.USD","LU0289739699.SGD","LU0109394709.USD","LU1585245621.USD","LU0114720955.EUR","IE00B19Z3581.USD","LU0882574055.USD","LU1066051498.USD","BK4550","IE00BSNM7G36.USD","LU1430594728.SGD","LU2089984988.USD","SG9999015945.SGD","BK4568","BK4139","LU1066053197.SGD","LU0058720904.USD","BK4532","BK4588","IE0002270589.USD","BK4578","LU0234570918.USD","LU1674673428.USD","LU2324357040.USD","LU1674673691.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2600921084","title":"Alvotech C/Wts (To Pur Com)股价拉升12.22% 市值涨452.75万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600921084","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600921084?lang=zh_cn&edition=full","pubTime":"2026-01-01 01:47","pubTimestamp":1767203221,"startTime":"0","endTime":"0","summary":"北京时间2026年01月01日01时47分，Alvotech C/Wts 股票出现波动，股价急速上涨12.22%。Alvotech C/Wts 股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，苏轩堂、Alvotech C/Wts 、Alvotech涨幅较大，Akanda Corp.、Cbdmd, Inc.、Inmed Pharmaceuticals Inc.较为活跃，换手率分别为24.82%、8.66%、5.65%，振幅较大的相关个股有Scilex Holding Company C/Wts 10/11/2027 、苏轩堂、Redhill Biopharma Ltd，振幅分别为43.16%、17.02%、12.14%。Alvotech C/Wts 公司简介：Alvotech是一家综合性生物制药公司，致力于为全球患者开发和生产高质量的生物仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101014701a6e66b2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101014701a6e66b2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALVOW","BK4139","ALVO"],"gpt_icon":0},{"id":"1165154234","title":"Alvotech宣布与合作伙伴Advanz Pharma共同在欧洲推出首款市场上首个生物仿制药Simponi®（Golimumab）","url":"https://stock-news.laohu8.com/highlight/detail?id=1165154234","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165154234?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:08","pubTimestamp":1766387313,"startTime":"0","endTime":"0","summary":"Alvotech宣布与合作伙伴Advanz Pharma共同在欧洲推出市场上首款生物仿制药Simponi®（Golimumab）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"1102537826","title":"Alvotech与美国商业合作伙伴达成与Regeneron Pharmaceuticals的和解及许可协议，计划在美国推出Avt06","url":"https://stock-news.laohu8.com/highlight/detail?id=1102537826","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102537826?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:47","pubTimestamp":1765979233,"startTime":"0","endTime":"0","summary":"Alvotech与美国商业合作伙伴达成了与Regeneron Pharmaceuticals的和解和许可协议，计划在美国推出Avt06。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"1151005021","title":"Alvotech Sa - 2026年指引考虑了获得美国FDA某些市场批准的进一步延迟影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1151005021","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151005021?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:43","pubTimestamp":1765979019,"startTime":"0","endTime":"0","summary":"Alvotech Sa - 2026年指引考虑了获得美国FDA某些市场批准的进一步延迟影响","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"2586254427","title":"Alvotech C/Wts (To Pur Com)股价上涨16.44% 市值跌33.22万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586254427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586254427?lang=zh_cn&edition=full","pubTime":"2025-11-26 04:53","pubTimestamp":1764104000,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日04时53分，Alvotech C/Wts 股票出现异动，股价大幅拉升16.44%。Alvotech C/Wts 股票所在的制药行业中，整体涨幅为2.81%。其相关个股中，Esperion Therapeutics, Inc.、Alvotech C/Wts 、Inmed Pharmaceuticals Inc.涨幅较大，Akanda Corp.、Inmed Pharmaceuticals Inc.、Gelteq Limited较为活跃，换手率分别为34.99%、17.72%、7.87%，振幅较大的相关个股有Scilex Holding Company C/Wts 10/11/2027 、Apimeds Pharmaceuticals Us, Inc.、Alvotech C/Wts ，振幅分别为37.59%、24.13%、17.67%。Alvotech C/Wts 公司简介：Alvotech是一家综合性生物制药公司，致力于为全球患者开发和生产高质量的生物仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126045320a7114a07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126045320a7114a07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALVO","ALVOW","BK4139"],"gpt_icon":0},{"id":"1178634012","title":"Alvotech宣布Avt03在欧洲经济区获得批准，成为Prolia®和Xgeva®（德诺单抗）的生物仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1178634012","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178634012?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:31","pubTimestamp":1763980305,"startTime":"0","endTime":"0","summary":"Alvotech宣布Avt03在欧洲经济区获得批准，成为Prolia®和Xgeva®（德诺单抗）的生物仿制药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"1177641728","title":"Alvotech和Advanz Pharma获得欧洲经济区对Gobivaz®的市场批准，这是一种首个上市的Simponi®（Golimumab）生物相似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1177641728","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177641728?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:01","pubTimestamp":1763629287,"startTime":"0","endTime":"0","summary":"Alvotech和Advanz Pharma获得欧洲经济区对Gobivaz®的市场批准，这是一种首个上市的Simponi®（Golimumab）生物相似药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"1119585301","title":"Alvotech SA 将2025年收入预期调整至5.7亿至6亿美金","url":"https://stock-news.laohu8.com/highlight/detail?id=1119585301","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119585301?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:24","pubTimestamp":1763569452,"startTime":"0","endTime":"0","summary":"11月2日 - Alvotech SA：修订2025年收入预期至5.7亿至6亿美金。美国FDA已向Alvotech发出关于AVT05生物制品许可申请的完整回应函。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"1181446260","title":"英国高等法院支持Alvotech，为Avt06的生产和市场准入铺平道路，该药物为Eylea®（Aflibercept）的生物仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1181446260","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181446260?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:02","pubTimestamp":1762765330,"startTime":"0","endTime":"0","summary":"英国高等法院支持Alvotech，为Avt06的生产和市场准入铺平道路，该药物为Eylea®（Aflibercept）的生物仿制药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"1101316823","title":"Alvotech和Advanz Pharma获得MHRA批准，推出Gobivaz®，这是一种Simponi®（Golimumab）的生物仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1101316823","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101316823?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:08","pubTimestamp":1762438108,"startTime":"0","endTime":"0","summary":"Alvotech和Advanz Pharma获得了MHRA的批准，推出Gobivaz®，这是一种Simponi®（Golimumab）的生物仿制药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0},{"id":"1170973158","title":"Alvotech于2025年11月13日举行网络直播，报告2025年前九个月的财务业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1170973158","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170973158?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290129,"startTime":"0","endTime":"0","summary":"Alvotech于2025年11月13日举行网络直播，报告2025年前九个月的财务业绩并提供业务更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"2581796987","title":"Alvotech C/Wts (To Pur Com)盘中异动 股价大跌8.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581796987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581796987?lang=zh_cn&edition=full","pubTime":"2025-11-05 01:17","pubTimestamp":1762276644,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日01时17分，Alvotech C/Wts 股票出现波动，股价大幅跳水8.11%。Alvotech C/Wts 股票所在的制药行业中，整体涨幅为0.73%。其相关个股中，Evoke Pharma, Inc.、Scilex Holding Company C/Wts 10/11/2027 、Scilex Holding Company涨幅较大，Evoke Pharma, Inc.、Redhill Biopharma Ltd、Hims & Hers Health, Inc.较为活跃，换手率分别为220.55%、25.59%、15.46%，振幅较大的相关个股有Scilex Holding Company C/Wts 10/11/2027 、Redhill Biopharma Ltd、Flora Growth Corp.，振幅分别为33.23%、33.06%、14.10%。Alvotech C/Wts 公司简介：Alvotech是一家综合性生物制药公司，致力于为全球患者开发和生产高质量的生物仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110501172494ef016c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110501172494ef016c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALVO","ALVOW"],"gpt_icon":0},{"id":"2574221181","title":"Alvotech C/Wts (To Pur Com)股价重挫13.61% 市值跌967.22万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574221181","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574221181?lang=zh_cn&edition=full","pubTime":"2025-10-09 21:33","pubTimestamp":1760016789,"startTime":"0","endTime":"0","summary":"北京时间2025年10月09日21时33分，Alvotech C/Wts 股票出现异动，股价急速跳水13.61%。截至发稿，该股报1.27美元/股，成交量1021股，换手率0.00%，振幅3.40%。Alvotech C/Wts 股票所在的制药行业中，整体涨幅为0.22%。Alvotech C/Wts 公司简介：Alvotech是一家综合性生物制药公司，致力于为全球患者开发和生产高质量的生物仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009213309a458608c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009213309a458608c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALVOW","ALVO","BK4139"],"gpt_icon":0},{"id":"1175694764","title":"Kashiv Biosciences宣布向美国FDA提交生物制品许可申请，欧洲药品管理局接受其Adl-018市场授权申请，该产品为Xolair®（奥马珠单抗）拟议生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1175694764","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175694764?lang=zh_cn&edition=full","pubTime":"2025-10-06 20:02","pubTimestamp":1759752138,"startTime":"0","endTime":"0","summary":"Kashiv Biosciences近日宣布，已向美国食品药品监督管理局（FDA）提交生物制品许可申请，同时欧洲药品管理局已接受其市场授权申请。此次申请涉及的产品为Adl-018，这是一款拟议的Xolair®（奥马珠单抗）生物类似药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO","BK4007","AMRX"],"gpt_icon":0},{"id":"1132589660","title":"Alvotech的Xolair®生物类似药Avt23欧洲营销许可申请获欧洲药品管理局接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1132589660","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132589660?lang=zh_cn&edition=full","pubTime":"2025-10-06 16:41","pubTimestamp":1759740101,"startTime":"0","endTime":"0","summary":"Alvotech针对其生物类似药候选产品Avt23的欧洲营销许可申请已获得欧洲药品管理局接受。Avt23是奥马珠单抗(Xolair®)的拟议生物类似药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALVO","BK4139"],"gpt_icon":0},{"id":"1184349745","title":"欧洲药品管理局推荐批准Alvotech拟议生物类似药Avt03的上市授权，作为Prolia®和Xgeva®的生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1184349745","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184349745?lang=zh_cn&edition=full","pubTime":"2025-09-22 18:16","pubTimestamp":1758536209,"startTime":"0","endTime":"0","summary":"欧洲药品管理局推荐批准Alvotech拟议生物类似药Avt03的上市授权，作为Prolia®和Xgeva®的生物类似药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alvotech.com","stockEarnings":[{"period":"1week","weight":-0.1078},{"period":"1month","weight":-0.1786},{"period":"3month","weight":-0.1946},{"period":"6month","weight":-0.5101},{"period":"1year","weight":-0.6462},{"period":"ytd","weight":-0.193}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alvotech于2021年8月23日根据卢森堡大公国法律注册成立。该公司是一家生物技术公司，由Robert Wessman创立，专注于为全球患者开发和制造生物仿制药。该公司通过提供高质量、具有成本效益的产品和服务，通过完全集成的方法和广泛的内部能力来寻求成为生物仿制药领域的全球领导者。该公司目前的产品线包含八种生物仿制药候选药物，旨在治疗自身免疫性疾病、眼部疾病、骨质疏松症、呼吸系统疾病和癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.097473},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.034594},{"month":3,"riseRate":0.2,"avgChangeRate":-0.094971},{"month":4,"riseRate":0.4,"avgChangeRate":-0.047178},{"month":5,"riseRate":0.4,"avgChangeRate":0.051716},{"month":6,"riseRate":0.2,"avgChangeRate":-0.114602},{"month":7,"riseRate":0.2,"avgChangeRate":0.0368},{"month":8,"riseRate":0.4,"avgChangeRate":0.00626},{"month":9,"riseRate":0.4,"avgChangeRate":-0.059202},{"month":10,"riseRate":0.4,"avgChangeRate":-0.014607},{"month":11,"riseRate":0.6,"avgChangeRate":-0.068468},{"month":12,"riseRate":0.833333,"avgChangeRate":0.164022}],"exchange":"NASDAQ","name":"Alvotech","nameEN":"Alvotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alvotech(ALVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alvotech(ALVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alvotech,ALVO,Alvotech股票,Alvotech股票老虎,Alvotech股票老虎国际,Alvotech行情,Alvotech股票行情,Alvotech股价,Alvotech股市,Alvotech股票价格,Alvotech股票交易,Alvotech股票购买,Alvotech股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alvotech(ALVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alvotech(ALVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}